Eliminating the Public Health Problem of Hepatitis B and C in the United States PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Eliminating the Public Health Problem of Hepatitis B and C in the United States PDF full book. Access full book title Eliminating the Public Health Problem of Hepatitis B and C in the United States by National Academies of Sciences, Engineering, and Medicine. Download full books in PDF and EPUB format.
Author: National Academies of Sciences, Engineering, and Medicine Publisher: National Academies Press ISBN: 0309438020 Category : Medical Languages : en Pages : 187
Book Description
Hepatitis B and C cause most cases of hepatitis in the United States and the world. The two diseases account for about a million deaths a year and 78 percent of world's hepatocellular carcinoma and more than half of all fatal cirrhosis. In 2013 viral hepatitis, of which hepatitis B virus (HBV) and hepatitis C virus (HCV) are the most common types, surpassed HIV and AIDS to become the seventh leading cause of death worldwide. The world now has the tools to prevent hepatitis B and cure hepatitis C. Perfect vaccination could eradicate HBV, but it would take two generations at least. In the meantime, there is no cure for the millions of people already infected. Conversely, there is no vaccine for HCV, but new direct-acting antivirals can cure 95 percent of chronic infections, though these drugs are unlikely to reach all chronically-infected people anytime soon. This report, the first of two, examines the feasibility of hepatitis B and C elimination in the United States and identifies critical success factors. The phase two report will outline a strategy for meeting the elimination goals discussed in this report.
Author: National Academies of Sciences, Engineering, and Medicine Publisher: National Academies Press ISBN: 0309438020 Category : Medical Languages : en Pages : 187
Book Description
Hepatitis B and C cause most cases of hepatitis in the United States and the world. The two diseases account for about a million deaths a year and 78 percent of world's hepatocellular carcinoma and more than half of all fatal cirrhosis. In 2013 viral hepatitis, of which hepatitis B virus (HBV) and hepatitis C virus (HCV) are the most common types, surpassed HIV and AIDS to become the seventh leading cause of death worldwide. The world now has the tools to prevent hepatitis B and cure hepatitis C. Perfect vaccination could eradicate HBV, but it would take two generations at least. In the meantime, there is no cure for the millions of people already infected. Conversely, there is no vaccine for HCV, but new direct-acting antivirals can cure 95 percent of chronic infections, though these drugs are unlikely to reach all chronically-infected people anytime soon. This report, the first of two, examines the feasibility of hepatitis B and C elimination in the United States and identifies critical success factors. The phase two report will outline a strategy for meeting the elimination goals discussed in this report.
Author: Mitchell L. Shiffman Publisher: Springer Science & Business Media ISBN: 1461411920 Category : Medical Languages : en Pages : 333
Book Description
Chronic Hepatitis C Virus: Lessons from the Past, Promise for the Future documents the monumental advances that have been made in our understanding of chronic HCV during the past decade. The first section reviews the natural history of chronic HCV, how this virus can affect other organs in addition to the liver, and whether treating chronic HCV alters the natural history of this disease. Section 2 reviews the advances that have been made in the treatment of chronic HCV during the past decade with interferon based therapy. Separate chapters on response guided therapy and how to manage the adverse events associated with these medications provide the physician with the concepts required to more effectively treat chronic HCV now and in the future. As the genetics of virologic response have recently been elucidated, a chapter is devoted to helping the clinician understand how genes that modulate disease processes and their treatment are identified and utilized in clinical care. Section 3 deals with the future of HCV treatment and specific inhibitors of HCV. Specific chapters explain how targets for drugs are identified and how drugs are then developed and tested; how mutations of HCV develop and how anti-viral agents will affect this process; the most up to date data regarding the treatment of chronic HCV with peginterferon, ribavirin and anti-viral agents; and the potential to treat chronic HCV with just oral anti-viral agents and without peginterferon and ribavirin in the future. The final section of this book covers issues related to liver transplantation in patients with chronic HCV. Separate chapters review the natural history of chronic HCV in liver transplant recipients and the impact of utilizing HCV positive donors. The volume concludes with chapters that cover the treatment of chronic HCV both prior to and after liver transplantation with potent anti-viral agents. Chronic Hepatitis C Virus: Lessons from the Past, Promise for the Future is a valuable resource for all physicians caring for patients with chronic HCV.
Author: Institute of Medicine Publisher: National Academies Press ISBN: 0309153689 Category : Medical Languages : en Pages : 252
Book Description
The global epidemic of hepatitis B and C is a serious public health problem. Hepatitis B and C are the major causes of chronic liver disease and liver cancer in the world. In the next 10 years, 150,000 people in the United States will die from liver disease or liver cancer associated with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections. Today, between 800,000 and 1.4 million people in the United States have chronic hepatitis B and between 2.7 and 3.9 million have chronic hepatitis C. People most at risk for hepatitis B and C often are the least likely to have access to medical services. Reducing the rates of illness and death associated with these diseases will require greater awareness and knowledge among health care workers, improved identification of at-risk people, and improved access to medical care. Hepatitis B is a vaccine-preventable disease. Although federal public health officials recommend that all newborns, children, and at-risk adults receive the vaccine, about 46,000 new acute cases of the HBV infection emerge each year, including 1,000 in infants who acquire the infection during birth from their HBV-positive mothers. Unfortunately, there is no vaccine for hepatitis C, which is transmitted by direct exposure to infectious blood. Hepatitis and Liver Cancer identifies missed opportunities related to the prevention and control of HBV and HCV infections. The book presents ways to reduce the numbers of new HBV and HCV infections and the morbidity and mortality related to chronic viral hepatitis. It identifies priorities for research, policy, and action geared toward federal, state, and local public health officials, stakeholder, and advocacy groups and professional organizations.
Author: Nancy Reau Publisher: Oxford University Press ISBN: 0190238291 Category : Medical Languages : en Pages : 201
Book Description
Fueled in part by the opioid epidemic, the number of reported hepatitis C virus infections tripled in the United States between 2010 and 2015. As new infections continue to mount, new therapies have produced seismic changes in how HCV is treated clinically, leaving a gap between the most current clinical guidance and the ongoing demands of patient care. The New Hepatitis C is a current and essential review of HCV's epidemiology, diagnosis, and clinical approaches -- a clinician's guidebook for navigating everything from screening to treatment. Acute and chronic HCV are addressed, as are important new treatment options for HCV, management of side effects, and a convenient summary of clinical trials on the treatment of chronic hepatitis C. Updated to detail the standards of care that will define the next decade of HCV management, this evidence-based volume is an essential clinical reference for to any practitioner in gastroenterology, hepatology, infectious disease, transplant, or internal medicine.
Author: World Health Organization Publisher: World Health Organization ISBN: 9789241549981 Category : Medical Languages : en Pages : 0
Book Description
Testing and diagnosis of hepatitis B (HBV) and C (HCV) infection is the gateway for access to both prevention and treatment services, and is a crucial component of an effective response to the hepatitis epidemic. Early identification of persons with chronic HBV or HCV infection enables them to receive the necessary care and treatment to prevent or delay progression of liver disease. Testing also provides an opportunity to link people to interventions to reduce transmission, through counselling on risk behaviors and provision of prevention commodities (such as sterile needles and syringes) and hepatitis B vaccination. These are the first WHO guidelines on testing for chronic HBV and HCV infection and complement published guidance by WHO on the prevention, care and treatment of chronic hepatitis C and hepatitis B infection. These guidelines outline the public health approach to strengthening and expanding current testing practices for HBV and HCV, and are intended for use across age groups and populations.
Author: Angelos Hatzakis Publisher: Springer Nature ISBN: 3030677621 Category : Medical Languages : en Pages : 219
Book Description
This volume provides the reader with a detailed overview of the current state-of-the art approach of Hepatitis C management. It reviews the course of action in handling of chronic Hepatitis C patients with various HCV genotypes and treats special cases such as acute hepatitis, transplant and renal patients as well as people who inject drugs. The two volume work on Hepatitis C introduces to the topic by reviewing virology, diagnosis, epidemiology, prevention, management and elimination of HCV. The book provides a valuable source at full length for researchers and clinicians working on Hepatitis C.
Author: National Academies of Sciences, Engineering, and Medicine Publisher: National Academies Press ISBN: 0309457297 Category : Medical Languages : en Pages : 297
Book Description
Hepatitis B and C cause most cases of hepatitis in the United States and the world. The two diseases account for about a million deaths a year and 78 percent of world's hepatocellular carcinoma and more than half of all fatal cirrhosis. In 2013 viral hepatitis, of which hepatitis B virus (HBV) and hepatitis C virus (HCV) are the most common types, surpassed HIV and AIDS to become the seventh leading cause of death worldwide. The world now has the tools to prevent hepatitis B and cure hepatitis C. Perfect vaccination could eradicate HBV, but it would take two generations at least. In the meantime, there is no cure for the millions of people already infected. Conversely, there is no vaccine for HCV, but new direct-acting antivirals can cure 95 percent of chronic infections, though these drugs are unlikely to reach all chronically-infected people anytime soon. This report, the second of two, builds off the conclusions of the first report and outlines a strategy for hepatitis reduction over time and specific actions to achieve them.
Author: Martina Smolic Publisher: BoD – Books on Demand ISBN: 9535135635 Category : Medical Languages : en Pages : 240
Book Description
In the past few years, remarkable progress has been made in our understanding of HCV biology, pathogenesis of infection, and structure-function relationships. This has led to quantum advances in clinical efficacy and tolerability. Yet, in spite of this amazing progress, there remain obstacles to widespread successful treatment. These issues include biological failures even with direct-acting agents, lack of options for individual with organ failures, drug-drug interactions, access to medications either due to lack of availability or affordability, and psychiatric and social issues. These problems are likely to remain in the future. Therefore, this book has been created by distinguished faculties from around the world to address the progress in our understanding of HCV infection and to review new treatment options, limitations, and accessibility of new therapeutic options.
Author: National Academies of Sciences, Engineering, and Medicine
Author: National Academies of Sciences, Engineering, and Medicine
Author: Mitchell L. Shiffman
Author: Institute of Medicine
Author: Nancy Reau
Author: Paul Arguin
Author: World Health Organization
Author: Angelos Hatzakis
Author: John Henkel
Author: National Academies of Sciences, Engineering, and Medicine
Author: Martina Smolic